India, Sept. 23 -- At the heart of pharmaceutical manufacturing lies a simple principle: medicines must be safe, effective, and reliable every single time. For Contract Development and Manufacturing Organizations (CDMOs), this requires more than regulatory compliance; it demands a quality culture that permeates every level of the organization. Indian CDMOs have been strengthening this culture steadily, and the results are visible. According to a 2024 study by the Indian Pharmaceutical Alliance and McKinsey, the proportion of US Food and Drug Administration (US FDA) "Official Action Indicated" (OAI) classifications for Indian facilities declined from 26% in 2014 to 13% in 2023, outperforming the global average of around 15%. Over the same ...